Most commercial AI roadmaps fund the exciting use case first and the highest-leverage one last. This guide gives Heads of Commercial Excellence the right order, a ranked, sourced sequence for both Pharma and CPG, with the dollar impact behind each decision.
95% of enterprise gen AI pilots show no measurable P&L impact, despite an estimated $30 to 40B in enterprise spend.
MIT NANDA, 2025 · cited in the guideThis is Week 3 of DecisionX's September series on Decision AI in Pharma and CPG, covering the CEO agenda, the CDO/CAIO architecture, this Commercial Excellence guide, Manufacturing Excellence, R&D Excellence, and a closing case study on what this actually returns.
Eleven questions. Two industries. One sourced sequence. Free, no spam, no sales pitch first.
Backed by McKinsey, BCG, ZS, KPMG and MIT NANDA research
Fill in your details below and we'll send the guide straight to your email.